Is Left Atrial Appendage Closure a True Alternative to NOACs?

For patients with non-valvular atrial fibrillation (AF), stroke prevention represents a primary therapeutic goal. Historically, clinicians have relied on direct oral anticoagulants (DOACs or NOACs) to mitigate thromboembolic risks. However, the landmark CHAMPION-AF clinical trial has recently introduced a compelling alternative. This pivotal study investigated whether left atrial appendage closure could match or even exceed the safety and efficacy of contemporary NOAC therapy over a three-year period. Consequently, these findings offer critical clinical insights for physicians managing atrial fibrillation.

Understanding Left Atrial Appendage Closure Efficacy

To evaluate the device, investigators randomized 3,000 atrial fibrillation patients to either the implant or NOAC therapy. Specifically, the study cohort presented a moderate stroke risk with an average CHA₂DS₂-VASc score of 3.5. After three years of follow-up, the primary efficacy endpoint occurred in 5.7% of the device group. In comparison, the oral anticoagulation group experienced an event rate of 4.8%. Therefore, the device successfully met the prespecified noninferiority criteria. This result is highly encouraging because it confirms that mechanical closure provides reliable protection.

A Major Victory for Long-Term Safety

While efficacy was comparable, the safety outcomes revealed a more pronounced divergence between the two strategies. The primary safety endpoint evaluated non-procedure-related bleeding, including major and clinically relevant non-major events. Significantly, the device group demonstrated a much lower bleeding rate of 10.9%. In contrast, patients on lifelong oral anticoagulants experienced a bleeding rate of 19.0%. This represents a 45% relative risk reduction in bleeding for patients who received the implant. Furthermore, this clinical benefit remained consistent across different age groups and post-ablation cohorts. Consequently, the treatment successfully achieved its primary safety objective, demonstrating statistical superiority. Thus, removing the need for lifelong anticoagulation directly translates into a lower long-term bleeding hazard.

Important Clinical Caveats and Nuances

Despite these highly favorable headlines, clinicians must carefully consider several practical limitations. For instance, the trial noted a slightly higher number of ischemic strokes in the device arm. Additionally, the primary safety endpoint did not capture acute procedural complications. Specifically, pericardial effusions requiring intervention occurred in 0.7% of patients during the first month. Moreover, roughly 4.8% of patients developed device-related thrombi at four months. Therefore, close imaging follow-up remains essential during the early post-implant phase. Ultimately, the decision to choose a device over medication requires careful, shared decision-making.

Frequently Asked Questions

Q1: What did the CHAMPION-AF trial reveal about left atrial appendage closure efficacy?

The trial demonstrated that left atrial appendage closure was noninferior to NOAC therapy at three years. Specifically, the composite efficacy endpoint occurred in 5.7% of patients in the device group and 4.8% in the oral anticoagulation group.

Q2: Did left atrial appendage closure reduce long-term bleeding risks?

Indeed, the device strategy significantly reduced non-procedure-related bleeding compared to oral anticoagulants. Consequently, the bleeding rate was 10.9% in the device group versus 19.0% in the NOAC group, representing a 45% relative risk reduction.

Q3: What are the early risks associated with left atrial appendage closure devices?

While the long-term safety profile is favorable, clinicians must monitor for early procedural complications. For instance, pericardial effusions requiring intervention occurred in 0.7% of patients within 30 days, and device-related thrombi occurred in 4.8% at four months.

References

1. Raco M et al. In AF, LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 y. Ann Intern Med. 2026 Jul 07. doi: 10.7326/ANNALS-26-02438-JC. PMID: 42407079.
2. Doshi SK, Kar S, Nair DG, et al. Outcomes in Patients with Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary 3-Year Results of the CHAMPION-AF Clinical Trial. N Engl J Med. 2026. doi: 10.1056/NEJMoa2517213.
3. Wazni OM, Saliba WI, Nair DG, et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. 2025;392(13):1277-1287. doi: 10.1056/NEJMoa2408308.